



## Screening men for osteoporosis

I have many middle-aged and elderly men in my family practice, including some who are being treated for osteoporosis, and thus I read with interest the *CMAJ* article on managing osteoporosis in men by Aliya Khan and colleagues.<sup>1</sup> I was surprised by the authors' statement that "as in the 2002 guidelines [from the Osteoporosis Society of Canada], [bone mineral testing] for all men over 65 is advised."

The article did not provide any evidence to support this recommendation, so I turned to the cited guidelines.<sup>2</sup> The first sentence in the section on osteoporosis in men states that "there are insufficient data on the relation between [bone mineral density] and fracture risk in men." Neither the guidelines nor the article by Khan and colleagues provides information on the incidence of osteoporosis in men. It would seem to me that any further discussion should be postponed until such data are available. However, both documents go on to recommend screening for men over 65 years of age.

How can one propose screening for a disease when the incidence of the condition is unknown in the population in question and when use of the recommended screening tool cannot as yet be correlated with disease detection? Furthermore, no evidence was provided concerning the cost of screening, the number of cases of osteoporosis that would be diagnosed by screening all men (rather than only men at

high risk of developing the disease) and the number of subsequent fractures that would be prevented by screening.

**Dara Behroozi MB BS**  
Clinical Associate Professor  
Department of Family Practice  
University of British Columbia  
Vancouver, BC

**Competing interests:** None declared.

### REFERENCES

1. Khan A, Hodsmann AB, Papaioannou A, et al. Management of osteoporosis in men: an update and case example. *CMAJ* 2007;176:345-8.
2. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada [published errata in *CMAJ* 2003;168:400, 2003;168:544 and 2003;168:676]. *CMAJ* 2002;167(Suppl 10):S1-34.

DOI:10.1503/cmaj.1070018

### [The authors respond:]

We thank Dara Behroozi for raising an important point concerning our article.<sup>1</sup> Unfortunately, the data currently available on the cost-effectiveness of bone densitometry in men are very limited. Schousboe and colleagues recently evaluated the cost-effectiveness of bone densitometry followed by 5 years of oral bisphosphonate therapy to prevent fractures among older men with osteoporosis in the United States.<sup>2</sup> They concluded that bone densitometry for all men as young as 70 years of age may be cost-effective. This assumes a societal willingness to pay US\$100 000 per quality-adjusted life-year gained in addition to drug costs. The Osteoporosis Society of Canada's guidelines emphasize assessing key clinical risk factors for fracture (e.g., previous fracture history and glucocorticoid use) in conjunction with bone mineral density testing to determine treatment thresholds.<sup>3</sup> In our article, we recommend targeting those at high risk of developing a fragility fracture for pharmacological intervention, which would improve the cost-effectiveness of treatment.

On the basis of current expert opinion, the Osteoporosis Society of Canada's recommendations for bone mineral density testing and clinical risk factor assessment are appropriate. It is true that in the absence of a defining fracture event, a low bone mineral density alone places a man at less risk for fracture than a woman of similar age with a similar bone mineral density. White men at age 60 have a 29% risk of experiencing a fracture.<sup>4</sup> One-third of all hip fractures occur in men; they are associated with equivalent morbidity and higher mortality compared with those occurring in women.<sup>5</sup> Vertebral fractures are also associated with similar morbidity in men and women.<sup>6</sup> More detailed Canadian studies will help to assess the cost-effectiveness of bone mineral density screening in men. The Osteoporosis Society of Canada is in the process of completing an exhaustive evidence-based review of osteoporosis in men, the results of which will be reflected in future guidelines.

**Aliya A. Khan MD**  
Divisions of Endocrinology and  
Geriatric Medicine  
McMaster University  
Oakville, Ont.

**Anthony B. Hodsmann MB BS**  
Divisions of Endocrinology and  
Nephrology  
University of Western Ontario  
London, Ont.

**Alexandra Papaioannou MSc MD**  
Division of Geriatric Medicine  
McMaster University  
Hamilton, Ont.

**David Kendler MD**  
Division of Endocrinology  
University of British Columbia  
Vancouver, BC

**Jacques P. Brown MD**  
Division of Rheumatology  
Laval University  
Québec City, Que.

**Wojciech P. Olszynski MD PhD**  
Division of Rheumatology  
University of Saskatchewan  
Saskatoon, Sask.

**Competing interests:** None declared by Wojciech Olszynski. Aliya Khan has received consultancy fees, research grants and/or honoraria from